search
Back to results

Characterization of Respiratory Microbiota in Susceptibility to Viral Respiratory Infections (RESPIBIOTE)

Primary Purpose

Viral Respiratory Infection

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
culturomic
Metagenomic
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Viral Respiratory Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adult > 18 years
  • Hospitalized patients with respiratory viral infection diagnosed by qPCR and / or rapid tests
  • Contact cases (parent, sister, brother, ...) of patients presenting with viral respiratory infection
  • No one has expressed opposition to the processing of personal data
  • Person who had been informed and had not expressed his opposition to participate in the study

Exclusion Criteria:

  • Minor patient
  • Subject who take antibiotic in the 3 weeks before the viral respiratory infection
  • Presence of another non-respiratory bacterial infection
  • Vulnerable person: Minor, person under guardianship, or deprived of liberty by a judicial or administrative decision

Sites / Locations

  • Assistance Publique Des Hopitaux de Marseille

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Other

Arm Label

symptomatic patients

asymptomatic patients

healthy subjects

Arm Description

symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed

symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed

Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed

Outcomes

Primary Outcome Measures

standard microbiological diagnosis of virology
qPCR influenza A, influenza B, rhinovirus, metapneumovirus and respiratory syncythial virus will be performed according to the laboratory protocol by PCR or immunochromatographic test.
Bacterial metagenomics
The composition of the respiratory microbiota will be established by high-throughput sequencing of the V3-V4 hypervariable regions of the 16S rRNA gene by Miseq (Illumina)
culturomic
Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry ( 14). In the event of an insufficient identification score by MALDI-TOF, the strains are identified by molecular techniques, in particular by sequencing of the 16S rRNA.

Secondary Outcome Measures

bacteria present in the respiratory flora in healthy group
Name of bacteria present in the resoiratory flora in healthy group
bacteria present in the respiratory flora of patients
Name of bacteria in the respiratory flora of patients with viral respiratory infection Identification mill be performed using culture approach.
Prognostic factors of viral respiratory infections
Prognostic factors (risk factors or protective factors) of viral respiratory infections by the identification of bacteria that play a protective or deleterious role in the occurrence of viral respiratory infection.

Full Information

First Posted
July 3, 2018
Last Updated
July 16, 2018
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT03600753
Brief Title
Characterization of Respiratory Microbiota in Susceptibility to Viral Respiratory Infections
Acronym
RESPIBIOTE
Official Title
Characterization of Respiratory Microbiota in Susceptibility to Viral Respiratory Infections Using Metagenomic and Culturomic Approach
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2018 (Anticipated)
Primary Completion Date
February 2021 (Anticipated)
Study Completion Date
October 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The role of the nasopharyngeal mucosal microbiota has recently been emphasized in respiratory diseases. The hypothesis that respiratory infections are linked to an imbalance of the nasopharyngeal microbiota has recently emerged and some studies show a link between the respiratory microbiota, the susceptibility to viral respiratory infections and the severity induced. In a preliminary work on the respiratory microbiota from 225 patients and 48 controls, the investigators found a decrease in the richness and biodiversity of the nasopharyngeal microbiota in patients with a respiratory viral infection as well as an enrichment of their respiratory flora in pathogenic bacteria. Interestingly, these recent years, the development of qPCR for virus diagnosis showed a substantial proportion of asymptomatic carriers of viruses suggesting that the nasopharyngeal microbiota may play a critical role in the genesis and clinical expression of viral respiratory infection, challenging Koch's postulate. The principal objectives of this study are to compare the respiratory microbiota between symptomatic patients with respiratory viral infection and asymptomatic carrier of virus. The aim is to determine the existence of respiratory microbiota profiles associated with the occurrence of viral respiratory infections influencing the clinical expression of virus and to determine the role of the respiratory microbiota in the occurrence of bacterial superinfection which will justify an early antibiotic treatment. The investigators will include 35 symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus), 35 asymptomatic patients with positive qPCR for respiratory virus and 30 healthy subjects (controls). A pharyngeal and a nasal swabs will be performed for each patient. All the samples will be analyse by culturomics and metagenomic. Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry.Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Detailed Description
The role of the nasopharyngeal mucosal microbiota has recently been emphasized in respiratory diseases. The hypothesis that respiratory infections are linked to an imbalance of the nasopharyngeal microbiota has recently emerged and some studies show a link between the respiratory microbiota, the susceptibility to viral respiratory infections and the severity induced. In a preliminary work on the respiratory microbiota from 225 patients and 48 controls, the investigators found a decrease in the richness and biodiversity of the nasopharyngeal microbiota in patients with a respiratory viral infection as well as an enrichment of their respiratory flora in pathogenic bacteria. Interestingly, these recent years, the development of qPCR for virus diagnosis showed a substantial proportion of asymptomatic carriers of viruses suggesting that the nasopharyngeal microbiota may play a critical role in the genesis and clinical expression of viral respiratory infection, challenging Koch's postulate. The principal objectives of this study are to compare the respiratory microbiota between symptomatic patients with respiratory viral infection and asymptomatic carrier of virus. The aim is to determine the existence of respiratory microbiota profiles associated with the occurrence of viral respiratory infections influencing the clinical expression of virus and to determine the role of the respiratory microbiota in the occurrence of bacterial superinfection which will justify an early antibiotic treatment. The investigators will include 35 symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus), 35 asymptomatic patients with positive qPCR for respiratory virus and 30 healthy subjects (controls). A pharyngeal and a nasal swabs will be performed for each patient. All the samples will be analyse by culturomics and metagenomic. Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry.Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene. The precise characterization of the respiratory microbiota in patients with viral respiratory infections is still incomplete. Our work is original because it will combine innovative and complementary techniques of culturomics and metagenomics for the exhaustive study of the respiratory microbiota associated with respiratory viral disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Viral Respiratory Infection

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
symptomatic patients
Arm Type
Experimental
Arm Description
symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
Arm Title
asymptomatic patients
Arm Type
Active Comparator
Arm Description
symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
Arm Title
healthy subjects
Arm Type
Other
Arm Description
Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
Intervention Type
Other
Intervention Name(s)
culturomic
Intervention Description
Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
Intervention Type
Other
Intervention Name(s)
Metagenomic
Intervention Description
Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Primary Outcome Measure Information:
Title
standard microbiological diagnosis of virology
Description
qPCR influenza A, influenza B, rhinovirus, metapneumovirus and respiratory syncythial virus will be performed according to the laboratory protocol by PCR or immunochromatographic test.
Time Frame
30 months
Title
Bacterial metagenomics
Description
The composition of the respiratory microbiota will be established by high-throughput sequencing of the V3-V4 hypervariable regions of the 16S rRNA gene by Miseq (Illumina)
Time Frame
30 months
Title
culturomic
Description
Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry ( 14). In the event of an insufficient identification score by MALDI-TOF, the strains are identified by molecular techniques, in particular by sequencing of the 16S rRNA.
Time Frame
30 months
Secondary Outcome Measure Information:
Title
bacteria present in the respiratory flora in healthy group
Description
Name of bacteria present in the resoiratory flora in healthy group
Time Frame
30 months
Title
bacteria present in the respiratory flora of patients
Description
Name of bacteria in the respiratory flora of patients with viral respiratory infection Identification mill be performed using culture approach.
Time Frame
30 months
Title
Prognostic factors of viral respiratory infections
Description
Prognostic factors (risk factors or protective factors) of viral respiratory infections by the identification of bacteria that play a protective or deleterious role in the occurrence of viral respiratory infection.
Time Frame
30 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult > 18 years Hospitalized patients with respiratory viral infection diagnosed by qPCR and / or rapid tests Contact cases (parent, sister, brother, ...) of patients presenting with viral respiratory infection No one has expressed opposition to the processing of personal data Person who had been informed and had not expressed his opposition to participate in the study Exclusion Criteria: Minor patient Subject who take antibiotic in the 3 weeks before the viral respiratory infection Presence of another non-respiratory bacterial infection Vulnerable person: Minor, person under guardianship, or deprived of liberty by a judicial or administrative decision
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie EDOUARD, MD
Phone
+33491385517
Email
sophie.edouard@univ-amu.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
EMILIE GARRIDO PRADALIE
Organizational Affiliation
APHM
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Des Hopitaux de Marseille
City
Marseille
State/Province
Paca
ZIP/Postal Code
13005
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
SOPHIE EDOUARD, MD
Phone
+33491385517
Email
sophie.edouard@univ-amu.fr
First Name & Middle Initial & Last Name & Degree
Jean-Christophe LAGUIER, MD
First Name & Middle Initial & Last Name & Degree
CAROLE ELDIN, MD
First Name & Middle Initial & Last Name & Degree
RAYMOND RUIMY, MD
First Name & Middle Initial & Last Name & Degree
CAMILLE AUBRY, MD
First Name & Middle Initial & Last Name & Degree
HERVE CHAUDET, MD

12. IPD Sharing Statement

Learn more about this trial

Characterization of Respiratory Microbiota in Susceptibility to Viral Respiratory Infections

We'll reach out to this number within 24 hrs